Cogmotiv is developing an innovative pharmacological treatment for apathy in dementia
Apathy is one of the most common, persistent and disabling neuropsychiatric syndromes, affecting > 60% of patients with dementia.
Our mission is to advance an innovative, scientifically grounded therapy that directly targets apathy in dementia - helping improve motivation, everyday engagement and quality of life for patients and their families.
Cogmotiv is privately held, early-stage biotech company established in 2025 in Vienna (Austria)
Wait for update...
Our Team
Dr. Jana Lubec
Founder & CEO
Dr. Petra Lührs
COO
Prof. Dr. Gert Lubec
Inventor & CSO
Joan Clavel
Business Lead
Advisors
Dr. Johann Leban
Inventor
Dr. Predrag Kalaba
The Florey
Supporters and Recognitions
©2025 Cogmotiv
